Loading...
Please wait, while we are loading the content...
Similar Documents
Is Your Practice Getting the Most from its EHR?
| Content Provider | Semantic Scholar |
|---|---|
| Author | Presant, Cary Arnett Bosserman, Linda D. McNatt, Wendy J. Emilio, Brandon |
| Copyright Year | 2009 |
| Abstract | 562. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide, with or without bevacizumab, in patients with stage II or stage III breast cancer. ASCO 2008. Available online at: www.asco.org. Last accessed May 20, 2009. 14Chang HR, Slamon D, Prati R, Glaspy J, et al. Abstract 10515. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity. ASCO 2006. Available online at: www.asco.org. Last accessed May 20, 2009. |
| Starting Page | 35 |
| Ending Page | 36 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| DOI | 10.1080/10463356.2009.11883761 |
| Volume Number | 24 |
| Alternate Webpage(s) | https://www.accc-cancer.org/docs/Documents/oncology-issues/articles/JA09/ja09-is-your-practice-getting-the-most-from-its-ehr |
| Alternate Webpage(s) | https://doi.org/10.1080/10463356.2009.11883761 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |